Head to head · SEC data as of September 11, 2026
Amgen
75
Quality score · out of 100
Gilead
54
Quality score · out of 100
Amgen comes in ahead: a quality score of 75 versus 54 for Gilead. Amgen wins on net margin (23% vs -10.6%), ROE (74.8% vs -27.4%) and revenue growth (7.6% vs 3.9%). Gilead answers with cash generation (FCF) (42.5% vs 26.7%) and less debt (-10.85× vs 2.69×).
| Metric | Amgen | Gilead |
|---|---|---|
| Quality score (0-100) | 75 | 54 |
| Net margin | 23% | -10.6% |
| Gross margin | — | — |
| ROE | 74.8% | -27.4% |
| Net debt/EBITDA | 2.69× | -10.85× |
| FCF margin | 26.7% | 42.5% |
| Revenue growth (annualized) | 7.6% | 3.9% |
| Earnings growth (annualized) | 5% | — |
TTM metrics with official SEC data, refreshed daily. Bold green marks the winner of each metric. A dash means the metric doesn't apply or isn't reliable.
Amgen. Amgen is one of the world's largest biotech companies. It specializes in biologic medicines —made from living cells— for serious diseases such as cancer and cardiovascular or inflammatory conditions. It has a broad portfolio and a strong dividend.
Gilead. Gilead Sciences is a large U.S. biotech. Its historic business is antivirals: it leads HIV treatment and revolutionized the cure for hepatitis C. It's now trying to diversify into oncology to depend less on a single area.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
What this comparison doesn't tell you
The score measures business quality, not whether the stock is cheap or expensive: the better company can be the worse investment if you overpay. For the valuation verdict, enter each one's current price in the analyzer:
Who has the stronger fundamentals today, Amgen or Gilead?
By the StockSemáforo model (profitability, growth and financial strength, built on official SEC data), Amgen scores higher: 75 versus 54 out of 100. The score is recomputed nightly with the latest filings.
Does that make Amgen the better investment?
No. The score measures business quality, not valuation: an excellent company can trade at an excessive price and be a poor investment at that price. To find out whether it's cheap or expensive, enter its current quote in the StockSemáforo analyzer.
Other comparisons
Pfizer vs Merck · Johnson & Johnson vs Pfizer · Eli Lilly vs AbbVie · UnitedHealth vs CVS Health · Merck vs Bristol Myers Squibb · See all comparisons →
Who's behind the methodology and model · how the score is computed
Data: official SEC filings (EDGAR) · Recomputed on September 11, 2026
Spotted a figure that looks wrong? Report it and we'll review it.